Johnson & Johnson $JNJ Stock Purchased by GAMMA Investing LLC

Key Points

• GAMMA Investing LLC increased its Johnson & Johnson stake by 8% in the third quarter, bringing its holdings to 84,832 shares valued at approximately $22.5 million. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson reported quarterly revenue of $25.31 billion and EPS of $2.90, exceeding analyst estimates, while revenue increased 6.6% year over year. The company also pays a $1.34 quarterly dividend, equivalent to a 2.1% yield.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $276.22, although risks include premium valuation, biosimilar competition, medical-device weakness, talc litigation and recent insider selling.

GAMMA Investing LLC increased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 84,832 shares of the company's stock after buying an additional 6,302 shares during the period. Johnson & Johnson accounts for about 0.7% of GAMMA Investing LLC's portfolio, making the stock its 21st largest position. GAMMA Investing LLC's holdings in Johnson & Johnson were worth $22,458,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Silver Coast Investments LLC increased its position in shares of Johnson & Johnson by 3.8% during the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after acquiring an additional 39 shares during the period. Townsend Asset Management Corp NC ADV boosted its holdings in shares of Johnson & Johnson by 0.6% in the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after purchasing an additional 39 shares during the period. Triumph Capital Management grew its stake in Johnson & Johnson by 1.6% in the second quarter. Triumph Capital Management now owns 2,531 shares of the company's stock worth $643,000 after purchasing an additional 39 shares in the last quarter. Kwmg LLC increased its holdings in Johnson & Johnson by 1.7% during the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company's stock worth $631,000 after purchasing an additional 39 shares during the period. Finally, Denali Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.2% in the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company's stock worth $839,000 after buying an additional 40 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,779,963.81. This trade represents a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 87,569 shares of company stock worth $23,064,544. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $256.85 on Friday. The company has a 50 day moving average price of $265.73 and a 200 day moving average price of $248.93. The firm has a market capitalization of $618.99 billion, a P/E ratio of 29.76, a PEG ratio of 2.59 and a beta of 0.21. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $184.66 and a 52 week high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter in the previous year, the firm earned $2.77 EPS. Johnson & Johnson's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Sell-side analysts expect that Johnson & Johnson will post 11.3 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is presently 62.11%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on JNJ. Guggenheim reissued a "buy" rating and set a $287.00 price target on shares of Johnson & Johnson in a research report on Wednesday. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a research note on Thursday, July 16th. Scotiabank reiterated an "outperform" rating and set a $305.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Tuesday, September 29th. Finally, Johnson Rice restated a "buy" rating on shares of Johnson & Johnson in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $276.22.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s oncology pipeline received favorable attention after Phase 3 data showed the Tecvayli–Talvey combination reduced the relative risk of disease progression or death by 89% and the risk of death by 62% in relapsed or refractory multiple myeloma. The results could support broader use of the therapies, although the combination remains investigational. 2026 Cancer Treatment Advances
• Positive Sentiment: Long-term Phase 3 psoriasis data for oral ICOTYDE reportedly showed maintained skin clearance and consistent safety through Week 112, potentially strengthening JNJ’s immunology pipeline and offering a targeted alternative for difficult-to-treat psoriasis. ICOTYDE Long-Term Psoriasis Data
• Positive Sentiment: Analyst support remains constructive: Guggenheim reaffirmed a Buy rating with a $287 price target, while other recent commentary describes JNJ as an increasingly growth-oriented healthcare company. JNJ Dividend Royalty Status
• Neutral Sentiment: Third-quarter earnings are approaching, with analysts focused on sales, margins, pharmaceutical growth, medical-device performance and management’s outlook for the September 2026 quarter. Forecast revisions or an earnings surprise could be the next major trading catalyst. JNJ Q3 Earnings Preview
• Negative Sentiment: Investors remain cautious because JNJ trades at a premium valuation relative to slower-growing pharmaceutical peers. Commentary also highlights biosimilar competition, a medical-device slowdown and ongoing talc litigation as risks that could limit upside or pressure investor confidence. JNJ Growth Stock Valuation

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.